Vatalanib is a small molecule protein kinase inhibitor that targets vascular endothelial growth factor receptors to inhibit angiogenesis, and it is investigated for use in combination with chemotherapy… Read more
Vatalanib is a small molecule protein kinase inhibitor that targets vascular endothelial growth factor receptors to inhibit angiogenesis, and it is investigated for use in combination with chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer. This category includes high-quality reference standards for Vatalanib, along with its associated impurities and related metabolites, which are essential for robust pharmaceutical research. Analytical laboratories rely on these compounds to perform precise impurity profiling, method validation, and rigorous quality control protocols. By utilizing well-characterized reference standards, researchers can accurately identify and quantify degradation products and synthetic by-products during stability testing and routine batch analysis. Furthermore, stable isotope labelled compounds within this selection provide internal standards necessary for accurate quantification in complex biological matrices, supporting the development and monitoring of this kinase inhibitor therapeutic.